Simulations Plus (Nasdaq:SLP) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

SLP 주식 개요

는 전 세계적으로 인공지능 및 머신러닝 기반 기술을 활용하여 모델링 및 시뮬레이션, 분자 특성 예측을 위한 신약 개발 및 개발 소프트웨어를 개발하는 회사입니다.

SLP 기본 분석
눈송이 점수
가치 평가	1/6
미래 성장	4/6
과거 실적	1/6
재무 상태	6/6
배당금	0/6

보상

수익은 매년 26.64% 증가할 것으로 예상됩니다.

지난 5년 동안 수입이 매년 5.7% 증가했습니다.

분석가들은 주가가 27.8% 상승할 것이라는 데 동의합니다.

위험 분석

재무 결과에 영향을 미치는 대규모 일회성 항목

Simulations Plus, Inc. 경쟁사

HealthStream

NasdaqGS:HSTM

US$838.4m

Doximity

NYSE:DOCS

US$5.0b

Forian

NasdaqCM:FORA

US$80.0m

Veeva Systems

NYSE:VEEV

US$29.7b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Simulations Plus
과거 주가
현재 주가	US$48.15
52주 최고치	US$52.69
52주 최저치	US$32.69
베타	0.75
11개월 변경	-3.66%
3개월 변경 사항	12.05%
1년 변경 사항	6.03%
33년 변화	-10.05%
5년 변화	68.59%
IPO 이후 변화	3,401.82%

최근 뉴스 및 업데이트

Recent updates

Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI

Feb 01

We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit

Jan 12

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Nov 06

Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Sep 06

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Jun 28

Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Feb 10

With EPS Growth And More, Simulations Plus (NASDAQ:SLP) Makes An Interesting Case

Nov 23

A Look At The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Oct 21

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Sep 19

Simulations Plus goes ex-dividend tomorrow

Jul 21

Simulations Plus Q3 2022 Earnings Preview

Jul 05

Simulations Plus (NASDAQ:SLP) Might Be Having Difficulty Using Its Capital Effectively

Jun 08

Estimating The Fair Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Mar 02

Simulations Plus: Software For The Pharma Industry, Significant Upside Potential

Mar 01

This Is Why We Think Simulations Plus, Inc.'s (NASDAQ:SLP) CEO Might Get A Pay Rise Approved By Shareholders

Feb 05

주주 수익률

	SLP	US Healthcare Services	US 마켓
7D	3.2%	-3.3%	0.4%
1Y	6.0%	-20.3%	22.9%

수익률 대 산업: SLP 지난 1년 동안 -21.4 %를 반환한 US Healthcare Services 산업을 초과했습니다.

수익률 대 시장: SLP 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is SLP's price volatile compared to industry and market?
SLP volatility
SLP Average Weekly Movement	8.3%
Healthcare Services Industry Average Movement	9.3%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.5%
10% least volatile stocks in US Market	2.9%

안정적인 주가: SLP 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: SLP 의 주간 변동성( 8% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
1996	195	Shawn O'Connor	www.simulations-plus.com

는 전 세계적으로 인공지능과 머신러닝 기반 기술을 활용하여 모델링 및 시뮬레이션, 분자 특성 예측을 위한 신약 개발 및 개발 소프트웨어를 개발하는 회사입니다. 이 회사는 소프트웨어와 서비스 두 부문으로 운영됩니다. 인간과 동물에게 투여되는 화합물의 흡수와 약물 상호작용을 시뮬레이션하는 GastroPlus와 DDDPlus 및 MembranePlus 시뮬레이션 제품을 제공합니다.

Simulations Plus, Inc. 기본 사항 요약

Simulations Plus 의 수익과 매출은 시가총액과 어떻게 비교하나요?
SLP 기본 통계
시가총액	US$943.89m
수익(TTM)	US$10.52m
수익(TTM)	US$64.67m

91.5x

P/E 비율

14.9x

P/S 비율

SLP 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
SLP 손익 계산서(TTM)
수익	US$64.67m
수익 비용	US$16.08m
총 이익	US$48.59m
기타 비용	US$38.08m
수익	US$10.52m

최근 보고된 수익

Feb 29, 2024

다음 수익 날짜

Jul 02, 2024

주당 순이익(EPS)	0.53
총 마진	75.14%
순이익 마진	16.26%
부채/자본 비율	0%

SLP 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

0.5%

현재 배당 수익률

46%

지급 비율

SLP 주식 개요

보상

위험 분석

Simulations Plus, Inc. 경쟁사

NasdaqGS:HSTM

US$838.4m

NYSE:DOCS

US$5.0b

NasdaqCM:FORA

US$80.0m

NYSE:VEEV

US$29.7b

가격 내역 및 성능

최근 뉴스 및 업데이트

Now 21% overvalued after recent price rise

Simulations Plus, Inc. to Report Q3, 2024 Results on Jul 02, 2024

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 12% to US$60.33

Simulations Plus, Inc. (NasdaqGS:SLP) acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders for approximately $100 million.

Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software

Recent updates

Now 21% overvalued after recent price rise

Simulations Plus, Inc. to Report Q3, 2024 Results on Jul 02, 2024

Consensus EPS estimates fall by 17%, revenue upgraded

Price target increased by 12% to US$60.33

Simulations Plus, Inc. (NasdaqGS:SLP) acquired Pro-ficiency, LLC from NovaQuest Capital Management, L.L.C., QHP Capital, L.P. and Pro-ficiency’s minority shareholders for approximately $100 million.

Simulations Plus Releases GastroPlus® X, The Next Generation PBPK/PBBM Modeling & Simulation Software

Simulations Plus: Reliance On Consulting And Acquisitions Creates Doubts

lead Independent Director notifies of intention to sell stock

Upcoming dividend of US$0.06 per share

Second quarter dividend of US$0.06 announced

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Now 43% overvalued after recent price rise

Simulations Plus, Inc. Declares a Cash Dividend, Payable on May 6, 2024

Why We're Not Concerned About Simulations Plus, Inc.'s (NASDAQ:SLP) Share Price

Simulations Plus, Inc. to Report Q2, 2024 Results on Apr 03, 2024

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Now 22% overvalued after recent price rise

Simulations Plus: Questionable Whether It Will Benefit Or Be Hurt By Generative AI

Simulations Plus, Inc. Releases GastroPlus Version 9.9

Upcoming dividend of US$0.06 per share at 0.6% yield

We Like Simulations Plus' (NASDAQ:SLP) Earnings For More Than Just Statutory Profit

First quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

President of PBPK notifies of intention to sell stock

Simulations Plus, Inc., Annual General Meeting, Feb 08, 2024

Simulations Plus, Inc. to Report Q1, 2024 Results on Jan 03, 2024

Simulations Plus, Inc. Reiterates Earnings Guidance for the Fiscal Year 2024

Capital Allocation Trends At Simulations Plus (NASDAQ:SLP) Aren't Ideal

Price target decreased by 9.1% to US$53.33

Simulations Plus, Inc. Declares Cash Dividend , Payable on November 6, 2023

Simulations Plus, Inc. to Report Q4, 2023 Results on Oct 25, 2023

Simulations Plus Receives New FDA Grant Award

Estimating The Intrinsic Value Of Simulations Plus, Inc. (NASDAQ:SLP)

Upcoming dividend of US$0.06 per share at 0.5% yield

Simulations Plus, Inc. Releases ADMET Predictor® 11

Third quarter 2023 earnings: Revenues and EPS in line with analyst expectations

Simulations Plus, Inc. Declares Cash Dividend , Payable on August 7, 2023

Co-Founder & Chairman notifies of intention to sell stock

Here's What's Concerning About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Simulations Plus, Inc. to Report Q3, 2023 Results on Jul 06, 2023

Simulations Plus, Inc. (NasdaqGS:SLP) acquired Immunetrics, Inc. from LaunchCyte LLC for $23.5 million.

Price target decreased by 12% to US$55.00

Upcoming dividend of US$0.06 per share at 0.5% yield

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

President exercised options to buy US$1.5m worth of stock.

President notifies of intention to sell stock

Simulations Plus Releases Redesigned NAFLDsym QSP Software Tool

Some Investors May Be Worried About Simulations Plus' (NASDAQ:SLP) Returns On Capital

Upcoming dividend of US$0.06 per share

Simulations Plus Releases DILIsym X (DSX) Beta with Redesigned Software Infrastructure

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Simulations Plus, Inc. (NasdaqGS:SLP) announces an Equity Buyback for $50 million worth of its shares.

Co-Founder & Chairman notifies of intention to sell stock

Simulations Plus, Inc., Annual General Meeting, Feb 09, 2023

Price target decreased to US$59.75

Simulations Plus, Inc. to Report Q1, 2023 Results on Jan 04, 2023

With EPS Growth And More, Simulations Plus (NASDAQ:SLP) Makes An Interesting Case

High number of new and inexperienced directors

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Simulations Plus, Inc. Announces Board Changes